Fosaprepitant

Fosaprepitant

Clinical data
AHFS/Drugs.com	Multum Consumer Information
MedlinePlus	a604003
License data	EU EMA: Ivemend US FDA: Fosaprepitant
Pregnancy category	US: B (No risk in non-human studies)
Routes of administration	Intravenous
ATC code	A04AD12 (WHO)
Legal status
Legal status	UK: POM (Prescription only) US: ℞-only
Pharmacokinetic data
Bioavailability	n/a
Protein binding	>95% (aprepitant)
Metabolism	To aprepitant
Biological half-life	9 to 13 hours (aprepitant)
Identifiers
IUPAC name [3-{[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl] ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl}-5-oxo- 2H-1,2,4-triazol-1-yl]phosphonic acid
CAS Number	172673-20-0 Y
PubChem CID	219090
IUPHAR/BPS	7623
DrugBank	DB06717 N
ChemSpider	189912 N
UNII	6L8OF9XRDC
KEGG	D06597 N
ChEBI	CHEBI:64321 N
ChEMBL	CHEMBL1199324 N
Chemical and physical data
Formula	C23H22F7N4O6P
Molar mass	614.406 g/mol
3D model (Jmol)	Interactive image
SMILES C[C@H](c1cc(cc(c1)C(F)(F)F)C(F)(F)F)O[C@@H]2[C@@H](N(CCO2)Cc3[nH]c(=O)n(n3)P(=O)(O)O)c4ccc(cc4)F
InChI InChI=1S/C23H22F7N4O6P/c1-12(14-8-15(22(25,26)27)10-16(9-14)23(28,29)30)40-20-19(13-2-4-17(24)5-3-13)33(6-7-39-20)11-18-31-21(35)34(32-18)41(36,37)38/h2-5,8-10,12,19-20H,6-7,11H2,1H3,(H,31,32,35)(H2,36,37,38)/t12-,19+,20-/m1/s1 N Key:BARDROPHSZEBKC-OITMNORJSA-N N
NY (what is this?)  (verify)

Fosaprepitant (Emend for Injection (US), Ivemend (EU)) is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant.

Fosaprepitant was developed by Merck & Co. and was approved by the United States Food and Drug Administration (FDA) on January 25, 2008 and by the European Medicines Agency (EMA) on January 11 of the same year.

See also

• Aprepitant
• Casopitant
• L-733,060
• Maropitant
• Vestipitant